Desmopressin as a pharmacological tool in vasopressinergic hypothalamus–pituitary–adrenal axis modulation: neuroendocrine, cardiovascular and coagulatory effects

GE Jacobs, EGJ Hulskotte, JMA van Gerven, L Zuurman, ML de Kam, J Elassaiss-Schaap, G Ruigt, J van Pelt, BWMM Peeters, PAM Peeters and J Burggraaf

J Psychopharmacol 2011 25: 353 originally published online 8 February 2010

DOI: 10.1177/0269881109358203

The online version of this article can be found at:

<http://jop.sagepub.com/content/25/3/353>

Published by:

<http://www.sagepublications.com>

On behalf of:

British Association for Psychopharmacology

Additional services and information for *Journal of Psychopharmacology* can be found at:

Email Alerts: <http://jop.sagepub.com/cgi/alerts>

Subscriptions: <http://jop.sagepub.com/subscriptions>

Reprints: <http://www.sagepub.com/journalsReprints.nav>

Permissions: <http://www.sagepub.com/journalsPermissions.nav>

>> **Version of Record** - Feb 25, 2011

OnlineFirst Version of Record - Mar 23, 2010

OnlineFirst Version of Record - Feb 8, 2010

What is This?

Desmopressin as a pharmacological tool in vasopressinergic hypothalamus–pituitary–adrenal axis modulation: neuroendocrine, cardiovascular and coagulatory effects

GE Jacobs¹, EGJ Hulskotte², JMA van Gerven¹, L Zuurman¹,
ML de Kam¹, J Ellassaïss-Schaap², G Ruigt², J van Pelt³,
BWMM Peeters², PAM Peeters² and J Burggraaf¹

Journal of Psychopharmacology

25(3) 353–360

© The Author(s) 2010

Reprints and permissions:

sagepub.co.uk/journalsPermissions.nav

DOI: 10.1177/0269881109358203

jop.sagepub.com

Abstract

Arginine-vasopressin (AVP) is a physiological co-activator of the hypothalamus–pituitary–adrenal (HPA) axis, together with corticotrophin releasing hormone (CRH). A synthetic analogue of AVP, desmopressin (dDAVP), is often used as a pharmacological tool to assess co-activation in health and disease. The relation between dDAVP's neuroendocrine, cardiovascular, pro-coagulatory, anti-diuretic and non-specific stress effects has not been studied. A randomized, double-blind, placebo-controlled, three-way crossover study was performed in 12 healthy male and female volunteers (6:6). dDAVP was administered intravenously as a 10 µg bolus (over 1 min) or a 30 µg incremental infusion (over 60 min). Neuroendocrine, cardiovascular, pro-coagulatory, anti-diuretic effects and adverse events (AEs) were recorded, and autonomic nervous system (ANS) activation evaluated. The incremental infusion reached 1.8-fold higher dDAVP concentrations than the bolus. Neuroendocrine effects were similar for the 10 µg dDAVP bolus and the 30 µg incremental infusion, while cardiovascular and coagulatory effects were greater with the 30 µg dose. Osmolality and ANS activity remained uninfluenced. AEs corresponded to dDAVP's side-effect profile. In conclusion, the neuroendocrine effects of a 10 µg dDAVP bolus administered over 1 min are similar to those of a 30 µg incremental infusion administered over one hour, despite higher dDAVP concentrations after the infusion. Cardiovascular and coagulatory effects showed clear dose-related responses. A 10 µg dDAVP bolus is considered a safe vasopressinergic function test at which no confounding effects of systemic or autonomic stress were seen.

Keywords

desmopressin, hypothalamus–pituitary–adrenal axis, vasopressin, function test, challenge, stress related psychopathology

Introduction

Arginine-vasopressin (AVP) is the nonapeptide modulator of the human vasopressinergic system. It acts as neurotransmitter within the central nervous system (CNS) and as neuroendocrine hormone in the peripheral circulation (Ring, 2005). AVP produced by hypothalamic parvocellular neurones of the medial paraventricular nucleus (PVN) is not only released into the CNS but also secreted into the pituitary portal circulation (Aguilera and Rabadan-Diehl, 2000; Scott and Dinan, 2002). Centrally-acting AVP is believed to play a role in the regulation of learning and memory, social behaviours, circadian rhythmicity and thermoregulation (Ring, 2005). Furthermore, following acute psychological and/or physical stress, it acts as co-activator of the hypothalamus–pituitary–adrenal (HPA) axis by inducing adrenocorticotrophic hormone (ACTH) release via the V_3 receptor (V_3 or V_{1b}) on the anterior pituitary (Dinan and Scott, 2005; Scott and Dinan, 1998). Co-activation is believed to occur in the presence of the main HPA axis activator corticotrophin releasing hormone (CRH) (Scott and Dinan, 2002). Subsequently, the stress hormone cortisol is released into the circulation from the adrenal cortices, causing various systemic and metabolic effects in peripheral tissues, and different behavioural and

cognitive effects in the central nervous system. In addition to these actions on the HPA-axis, AVP originating from magnocellular neurons of the supraoptic nucleus and PVN of the hypothalamus is secreted peripherally via the posterior pituitary (Ring, 2005). Peripheral release is triggered by hypo-osmolality, hypovolemia, reduced blood pressure, haemorrhage, hypoglycaemia, fever and pain. After release, it acts principally at V_{1a} receptors of the renal tubular cells restoring plasma volume and osmolality (Ring, 2005).

Hyperactivity of the AVP system of the anterior pituitary has been implicated in HPA axis dysregulation during chronic stress-related psychopathology (Pariante and Lightman, 2008; Scott and Dinan, 2002). Preclinical data indicate that AVP sustains HPA axis hyperactivity under conditions of

¹Centre for Human Drug Research, Leiden, The Netherlands.

²NV Organon, part of Schering-Plough Corporation, Department of Clinical Pharmacology and Kinetics, Oss, The Netherlands.

³Department of Clinical Chemistry, Leiden University Medical Centre, Leiden, The Netherlands.

Corresponding author:

Gabriel Jacobs, Centre for Human Drug Research, Zernikedeef 10, 2333 CL Leiden, The Netherlands. Email: gjacobs@chdr.nl

chronic stress (Spiga et al., 2009). Humans with (subtypes of) depressive disorder display hypercortisolism, indicating chronic HPA axis hyperactivation. Also, these patients have an enhanced neuroendocrine response to the combined dexamethasone–corticotrophin release hormone (DEX/hCRH) function test. This potentiation of the response to hCRH is predominantly ascribed to pre-existing hypersensitivity of the AVP system (Holsboer, 1983, 2000). However, the exact role of AVP in the pathophysiology of different (sub)types of affective disorders or other psychiatric conditions has not been clearly defined.

The lack of a better understanding of the role of AVP in psychopathology is in part related to the lack of validated function tests of vasopressinergic HPA axis regulation. A reliable pharmacological vasopressinergic function test would not only be useful in examining AVP in HPA axis regulation in health and (psychiatric) disease in more detail, but it would also be helpful to investigate innovative drugs targeting this system. Modulation of the AVP system by V_3 antagonists could, for instance, be clearly demonstrated in an early stage of drug development by suppression of the HPA effects induced by a validated AVP function test. Such a function test can also be used as functional diagnostic and/or prognostic tool in patients suffering from HPA axis associated psychiatric disorders. Previously, intravenous (i.v.) administration of desmopressin (dDAVP), a synthetic analogue of AVP, has been proposed as pharmacological function test of vasopressinergic HPA axis function (Dinan and Scott, 2005; Scott and Dinan, 1998). dDAVP is a partially specific vasopressin receptor agonist exhibiting pharmacological activity at the V_3 as well as the vasopressin 2 receptors (V_2) (Craighead et al., 2008). It has an elimination half-life of 0.9 to 3.8 hours and is excreted unchanged by the kidneys (Rembratt et al., 2004). In the past, a number of important studies have utilized dDAVP to help understand AVP's role in the (patho)physiology of HPA axis regulation (Dinan et al., 1999, 2004; Scott et al., 1999a,b). However, to a large extent these studies have focussed on the magnitude of V_3 modulated neuroendocrine pharmacodynamic (PD) effects with minimal attention for systemic effects that may confound HPA axis activation by non-specific stress, or affect the safety of this test. Specifically, the influence of blood pressure reduction induced by dDAVP via the V_2 and its potential subsequent influence on ACTH release via the autonomic nervous system (ANS) remains unclear. There is also very little information on the procoagulant and anti-diuretic adverse effects of i.v. administered $10\mu\text{g}$ dDAVP via the V_2 . These effects are particularly relevant if the dDAVP function test is to be applied in depressed patient populations, who have an increased risk for comorbid cardiovascular disease or (components of) the metabolic syndrome (Evans et al., 2005; Musselman et al., 2003; Ramasubbu, 2002).

We performed a study simultaneously investigating the neuroendocrine, cardiovascular, anti-diuretic, pro-coagulant and (indirect) ANS effects of dDAVP, and their concentration and infusion rate dependence. Two different doses of dDAVP were administered i.v. using two different administration modes: (1) $10\mu\text{g}$ dDAVP was administered as a bolus over 60 s and (2) $30\mu\text{g}$ dDAVP was administered incrementally over a period of 60 min. The $10\mu\text{g}$ dose was previously

shown to be the minimum dose able to induce vasopressinergic HPA axis activation, whereas an incremental dose of $30\mu\text{g}$ was expected to produce comparable peak dDAVP plasma levels (C_{max}) (Agero et al., 2004). In this regard, it is important to note that the predictability of this approach is limited since previous pharmacokinetic analyses have reported more than two-fold differences in clearance and 100-fold differences in C_{max} of i.v. administered dDAVP (Callreus et al., 1999; Fjellestad-Paulsen et al., 1996; Odeberg et al., 2004; Rembratt et al., 2004). At any rate, the use of two different infusion paradigms was to provide an impression on how the different peripheral and central effects of dDAVP were influenced by concentrations and infusion rates.

Methods

Study design

A randomized, double-blind, double-dummy infusion, placebo-controlled, three-way crossover study was performed in 12 healthy volunteers. The study protocol was approved by the Medical Ethics Committee of Leiden University Medical Centre (LUMC) and performed according to Good Clinical Practice and International Conference on Harmonisation guidelines.

Main outcome measures

The main PD outcome measures were dDAVP's (1) neuroendocrine effects (serum ACTH, cortisol) and (2) cardiovascular effects (systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR)). Furthermore, dDAVP's effect on coagulation was assessed by measuring plasma Von Willebrand factor (vWF) and its antidiuretic effects were investigated by measuring serum osmolality. dDAVP-modulated ANS activation was assessed indirectly by measuring serum prolactin and saliva alpha amylase. Adverse events (AEs) were recorded throughout the trial.

Drug administration

The incremental infusion consisted of cumulative i.v. doses of dDAVP $30\mu\text{g}$ over 60 min (0 to 60 min). The infusion rate was increased every 5 min for the first 30 min up an infusion rate of $40\mu\text{g/h}$, after which the infusion rate remained constant at $40\mu\text{g/h}$ for the remaining 30 min. At 50 min an intravenous bolus of $10\mu\text{g}$ dDAVP was administered over 60 seconds.

Volunteers

Twelve healthy volunteers (six male and six female) participated in the study. After obtaining written informed consent, the subjects underwent a full medical screening to assess eligibility. Volunteers were excluded from study participation if they were (1) using more than four units alcohol on average per day; (2) smoking more than five cigarettes per day; (3) using any drug (except oral contraceptives for females) or substance within one week before the first dosing; (4) using any drug or substance known to influence the metabolism of dDAVP in the month preceding the trial; (5) demonstrating

an ADAMTS-13 deficiency or presenting with a personal or family history of hypercoagulability as reflected by a diagnosis of coagulation factor deficiency (e.g. Factor V Leiden mutation, APC resistance) or previous pulmonary embolism, deep venous thrombosis or other (arterial) cardiovascular disease, (6) presenting with a personal or family history of renal disease including diabetes insipidus and symptoms such as polydipsia, (7) presenting with a personal or a first-degree family history of a clinical significant psychiatric disorder according to DSM-IV. Xanthine containing foods or beverages, tobacco or alcohol were not allowed during the stay on the research unit. Concomitant medication other than paracetamol was not permitted during the study period.

dDAVP

dDAVP (Octostim®) and placebo (0.9% NaCl) were prepared for administration by Profil GmbH, Neuss, Germany and were identical in appearance.

Study days

Volunteers arrived at the Centre for Human Drug Research (CHDR) on the evening before the study day. On admission, urinary screening was performed for drug abuse using the OnCall™ Test (ACON Laboratories Inc., San Diego, CA 92121, USA) and Rapid Assays for Drug Abuse (Instruchemie Hilversum B.V. the Netherlands), and qualitative colour immunochromatographic urinary hCG was performed in all female subjects using the OnCall test device. Volunteers went to bed at 23:00 and were woken up around 08:00 the next morning after which a standardized breakfast was served. Two cannulas were inserted into the antecubital vein of each arm for blood sampling and intravenous administration of dDAVP. This occurred at least one hour before the first PD blood sampling to allow any potential procedure-related HPA axis activation to return to baseline. Fluid intake was restricted to 900 ml water administered at fixed time points and subjects remained supine on the bed for the first four hours after start of the incremental infusion. At 0 min either 30 µg dDAVP or placebo was infused incrementally for 30 min followed by a constant infusion rate for 30 min. At 0 and 50 min dDAVP or placebo was administered as described above. Administration of the i.v. infusions was performed under hospital conditions and a research physician attended all study occasions. At the end of the study day, volunteers were discharged from the research unit only after having produced urine. Adverse events were registered from spontaneous reports and hourly inquiries.

Biochemical measurements

Venous blood (1.2 ml; prechilled EDTA tubes) was collected for the determination of plasma ACTH 20 and 10 min before and 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 100, 110, 120, 140, 160, 180, 210, 240, 270 and 480 min after the start of the incremental infusion. Samples were immediately placed on ice, processed within 30 min and stored at -80°C . Samples were analysed within 6 weeks using the Immulite 2500 Analyzer Assay (EURO/DPC,

United Kingdom) at the Central Laboratories of LUMC. Venous blood (1.2 ml; serum tubes) for the assay of serum cortisol and prolactin was taken 20 and 10 min before and 10, 20, 25, 30, 35, 40, 45, 55, 60, 65, 70, 75, 80, 90, 100, 120, 140, 160, 180, 210, 240, 270 and 480 min after the start of the incremental infusion. Samples were stored for 30–45 min at ambient temperature to allow coagulation, subsequently centrifuged for 15 min at 2000g and stored at -20°C . Samples were analysed using Perkin Elmer AutoDelfia Testkits at Organon Development GmbH, Department of Bioanalytics, Waltrop, Germany. Venous blood (2 ml; EDTA tubes) was obtained for plasma dDAVP 10 min before and 10, 20, 25, 30, 35, 40, 45, 55, 60, 65, 70, 75, 80, 90, 120, 180, 240 and 480 min after start of the incremental infusion. Samples were inverted, centrifuged within 15 min after collection for 15 min between 2000g and 3000g and stored at -20°C . dDAVP was analysed using liquid chromatography mass spectrometry (LC-MS/MS) at Xendo Drug Development BV, Groningen, The Netherlands. It appeared that the stability of dDAVP in human plasma, under the storage conditions used, was not demonstrated to cover the length of time from sample collection to analysis (accuracy against value at 0 min was $>15\%$). Therefore, only relative and no absolute dDAVP concentrations are reported. We collected 1.2 ml venous blood in citrate 0.106 mol/l collection tubes for vWF 10 min before and 30, 60, 90, 120 and 240 min after the start of the incremental infusion. Samples were centrifuged within 30 min for 20 min at 2000g and 4°C , frozen according to the 'snap freeze' method and stored at -40°C . Samples were analysed at the Laboratory of TNO Pharma, Leiden, the Netherlands. We collected 1.2 ml blood in serum clotting activator tubes for serum osmolality 10 min before and 30, 60, 90, 120, 150, 180 and 240 min after the start of the incremental infusion. Samples were stored for 30–45 min at ambient temperature to allow coagulation, subsequently centrifuged for 10 min at 2000g and 4°C and stored refrigerated until analysis at the end of the collection day. Samples were analysed by molecular freezing-point depression with an Osmometer OM-6050 of Arkry (Japan) at the Central Laboratories of LUMC.

Vital signs

Blood pressure and pulse rate were measured continuously from 15 min prior until 4 h after the start of infusion using the Finapres methodology (Finapres Medical Systems BV, Amsterdam The Netherlands) and Nihon-Kohden (BSM-1100) or Colin (Pressmate BP-8800) blood pressure apparatus. Electrocardiogram (ECG) recordings were made 30 min before and 180 min after.

Data analysis

Neuroendocrine parameters (ACTH, cortisol), cardiovascular parameters (SBP, DBP, HR), serum osmolality, vWF and indirect ANS effects (prolactin, saliva alpha amylase) were analysed by mixed model analyses of variance (using SAS PROC MIXED) with treatment, time, gender, gender-by-treatment and treatment-by-time as fixed effects, with subject and subject-by-time as random effects, and with the average baseline value as a covariate.

The neuroendocrine parameters, prolactin and serum osmolality were log-transformed prior to analysis. The contrasts between placebo and the bolus and between placebo and the incremental infusion were calculated over different time periods: for the incremental infusion over the period 0 to 180 min, and for the bolus infusion over 50 to 180 min since it was administered from 50 to 51 min. Contrasts were reported as placebo versus bolus infusion, placebo versus incremental infusion and bolus infusion versus incremental infusion. Results were presented as average differences compared with placebo (in percentages when back transformed from log-transformed variables) with 95% confidence intervals. The pharmacokinetic analysis of dDAVP consisted of determining the maximal mean plasma concentration ($C_{\max}$).

Results

Subject disposition and demographic data

Eighteen volunteers were screened after having provided informed consent. Four subjects did not comply with the inclusion and exclusion criteria and were excluded from participation. Twelve volunteers received study medication of which one dropped out due an AE not related to study medication. The mean age of the volunteers was 21 years (range 18–27 years) and was similar for males and females. Females had a mean weight of 65 kg (60–67 kg) and mean height of 1.73 m (range 1.68–1.84 m). Males had a mean weight of 80 kg (range 63–99 kg) and mean height of 1.88 m (range 1.83–1.90 m).

Adverse events

All AEs were of mild to moderate intensity, transitory in nature and had mostly dissipated within 12 hours after drug administration. AEs were predictable based on the side-effect profile of dDAVP and no subjects discontinued participation directly due to related adverse effects. The most commonly occurring AEs were: light-headedness (2/12 subjects), headache (2/12 subjects) and fatigue (2/12 subjects) for placebo; facial flushing (5/12 subjects), headache (5/12 subjects), fatigue (3/12 subjects) and dizziness (2/12 subjects) for the incremental infusion; and facial flushing (8/11 subjects), dizziness (4/11 subjects) and headache (4/11 subjects) for the bolus infusion.

Pharmacokinetics

In contrast to the expectation, a 1.8-fold higher maximal dDAVP concentration was reached during the incremental infusion compared with the bolus infusion. The maximal dDAVP concentration was reached 55 min after start of the incremental infusion and 5 min after the start of the bolus infusion, i.e. at 55 min for both administration modes.

Neuroendocrine pharmacodynamic effects

Mean ACTH release was statistically significant for both the bolus +26.1 (5.8, 50.3)% and incremental +30.9 (11.1, 54.2)% infusions compared with placebo, but the difference

between the two infusion regimens was not significant (Table 1). Maximal mean ACTH concentrations were also comparable with 15.85 and 15.02 ng/l for the bolus and incremental infusions, respectively. The maximal mean ACTH concentration was attained at 55 min, 5 min after the $C_{\max}$ of dDAVP for both the bolus and incremental infusions. Mean cortisol levels increased with +18.9 (4.1, 35.8)% for the bolus and +17.7 (3.5, 33.8)% for the incremental infusion compared to placebo (Table 1). The maximal mean concentrations of cortisol, attained 15 min after those of ACTH, were very similar at 160.22 and 158.25 ng/ml for the bolus and incremental infusions, respectively. The effects on ACTH and cortisol are illustrated in Figures 1 and 2.

Pro-coagulant and anti-diuretic effects

vWF was released after dDAVP administration, with higher levels attained with the 30 μ g incremental infusion. Compared with placebo, the incremental infusion led to an increase of +104 (84, 124)%. A smaller increase of +64.0 (41, 86)% was observed with the bolus infusion (Table 2). Although the levels of vWF-Ag tended to decrease from 120 min onwards, they had not returned to baseline at the end of the measurement period (480 min). Furthermore, serum osmolality was not altered by either the bolus or the incremental infusion.

Cardiovascular pharmacodynamic effects

The incremental infusion had larger blood pressure lowering effects than the bolus infusion. HR increased compensatory with both infusions. These effects are illustrated best for DBP and HR in Figures 3 and 4. After the bolus, rapid but short lasting circulatory effects were recorded. Similar maximum cardiovascular changes occurred during the incremental infusion, but these effects appeared and disappeared more gradually than after the bolus. Compared with placebo, the bolus infusion decreased average SBP by -3.2 (-6.7 , 0.3) mmHg and DBP by -7.2 (-10.2 , -4.3) mmHg, and increased HR by $+6.0$ (1.2 , 10.7) bpm. These effects were somewhat smaller than after the incremental infusion, which decreased average SBP by -5.3 (-8.6 , -2.0) mmHg and DBP by -8.5 (-11.2 , -5.8) mmHg, and increased HR by $+9.7$ (5.1 , 14.4) bpm (Table 2).

Measures of dDAVP-induced ANS activation

Serum prolactin was not consistently affected by either dDAVP infusion. The incremental infusion decreased prolactin significantly by -15.4 (-23.5 , -6.4)% while the bolus infusion increased prolactin non-significantly by $+6.1$ (-5.2 , 18.8)% compared with placebo. Saliva alpha-amylase increased non-significantly by $+11.4$ (-14.5 , 45.2)% following the incremental infusion and by $+13.6$ (-13.9 , 50.0)% after the bolus infusion.

Discussion

In this study we aimed to concomitantly investigate neuroendocrine, cardiovascular, antidiuretic, procoagulatory and (indirect) ANS effects of i.v. dDAVP, administered using

Table 1. Pharmacodynamic (PD) parameters for the period 50 min to three hours for the bolus infusion and over three hours for the incremental infusion, and estimated means (back transformed least square means [LSM]) for plasma ACTH (nmol/l), serum cortisol (ng/ml), serum prolactin (ng/ml) and saliva alpha-amylase (U/ml) for placebo, 10 µg dDAVP bolus infusion and 30 µg dDAVP incremental infusion. Estimated difference (%) with 95% confidence interval from placebo for 10 µg dDAVP bolus infusion and 30 µg dDAVP incremental infusion and the estimated difference (%) with 95% confidence interval between 10 µg dDAVP bolus infusion and 30 µg dDAVP incremental infusion

PD parameter	Back transformed LSM			Estimated difference with 95% confidence interval (%)		
	Placebo (<i>n</i> = 12)	10 µg dDAVP bolus infusion (<i>n</i> = 11)	30 µg dDAVP incremental infusion (<i>n</i> = 12)	Treatment <i>p</i> -value	Bolus infusion versus placebo 50–180 min	Incremental infusion versus placebo 0–180 min
	50–180 min	0–180 min	0–180 min			
Plasma ACTH (ng/l)	9.62	9.73	12.13	0.011	+26.1 (5.8, 50.3) <i>p</i> = 0.013	+30.9 (11.1, 54.2) <i>p</i> = 0.003
Serum cortisol (ng/ml)	117.91	125.46	140.21	0.036	+18.9 (4.1, 35.8) <i>p</i> = 0.014	+17.7 (3.5, 33.8) <i>p</i> = 0.016
Serum prolactin (ng/ml)	4.33	4.54	4.59	0.001	+6.1 (–50.2, 18.8) <i>p</i> = 0.281	–15.4 (–23.5, –6.4) <i>p</i> = 0.03
Saliva alpha-amylase (U/ml)	110.71	107.56	125.77	0.689	+13.6 (–13.9, 50.0) <i>p</i> = 0.350	+11.4 (–14.5, 45.2) <i>p</i> = 0.404
						Bolus versus incremental
						+13.0 (–5.0, 34.4) <i>p</i> = 0.155
						+2.9 (–9.9, 17.5) <i>p</i> = 0.66
						–19.0 (–27.5, –9.5) <i>p</i> = 0.001
						+7.9 (–18.0, 50.0) <i>p</i> = 0.568

Figure 1. Average concentration time profile of plasma adrenocorticotrophic hormone (ACTH) with SD error bars (closed circle: placebo; open circle: incremental infusion; open square: bolus infusion).

Figure 2. Average concentration time profile of serum cortisol with SD error bars (closed circle: placebo; open circle: incremental infusion; open square: bolus infusion).

Figure 3. Average concentration time profile of diastolic blood pressure (DBP) with SD error bars (closed circle: placebo; open circle: incremental infusion; open square: bolus infusion).

Figure 4. Average concentration time profile of heart rate (HR) with SD error bars (closed circle: placebo; open circle: incremental infusion; open square: bolus infusion).

Table 2. Cardiovascular, coagulatory and anti-diuretic parameters for the period 50 min to three hours for the bolus infusion and over three hours for the incremental infusion: estimated difference (%) with 95% confidence interval from placebo for 10 µg dDAVP bolus infusion and 30 µg dDAVP incremental infusion and the estimated difference (%) with 95% confidence interval between 10 µg dDAVP bolus infusion and 30 µg dDAVP incremental infusion for systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), von Willebrand factor (vWF) and serum osmolality

Parameter	Estimated difference with 95% confidence interval (%)		
	Bolus infusion versus placebo 50–180 min	Incremental infusion versus placebo 0–180 min	Bolus versus incremental
SBP (mmHg)	–3.2 (–6.7, 0.3) $p = 0.0715$	–5.3 (–8.6, –2.0) $p = 0.0036$	–2.3 (–5.7, 1.1) $p = 0.1722$
DBP (mmHg)	–7.2 (–10.2, –4.3) $p < 0.0001$	–8.5 (–11.2, –5.8) $p < 0.0001$	–2.1 (–5.0, 0.08) $p = 0.1473$
HR (bpm)	+6.0 (1.2, 10.7) $p = 0.016$	+9.7 (5.1, 14.4) $p = 0.000$	+5.7 (1.0, 10.4) $p = 0.020$
vWF (%)	+64.0 (41, 86) $p < 0.000$	+104.0 (84, 124) $p < 0.000$	+58.0 (36, 80) $p < 0.000$
Serum osmolality (mOsmol/kg)	–0.2 (–0.6, 0.3) $p = 0.446$	–0.2 (–0.6, 0.1) $p = 0.199$	–0.1 (–0.6, 0.4) $p = 0.644$

two different dosing regimens. dDAVP could be a useful pharmacological function test of vasopressinergic activation of the HPA axis to study the involvement of this system in normal or abnormal (psycho)physiology and during treatment. The study showed differences in neuroendocrine, coagulatory and cardiovascular effects between a slow incremental infusion of 30 µg and a rapid intravenous bolus of 10 µg in healthy volunteers.

AVP is a physiological co-activator of the HPA-axis, mediated by V_3 -receptors on anterior pituitary corticotrophes and requiring the presence of endogenously available CRH to release ACTH (Dinan and Scott, 2005; Ring, 2005). We found small but statistically significant increases in ACTH and cortisol release after administering either 10 µg dDAVP over 1 min or 30 µg dDAVP over 60 min. Both administration modes induced comparable elevations of ACTH and cortisol, despite an almost two-fold higher maximum dDAVP concentration reached with the incremental infusion compared to the bolus. The maximum serum cortisol concentrations of roughly 160 ng/ml after dDAVP were only 50–70% of the levels attained previously with serotonergic and corticotrophinergic function tests. Meta-chlorophenylpiperazine (mCPP) 0.5 mg/kg administered i.v. lead to a cortisol $C_{\max}$ 228.4 ng/ml (Gijssman et al., 1998), 5-hydroxytryptophan (5-HTP) 300 mg administered orally induced a cortisol $C_{\max}$ of 218.9 ng/ml (Smarius et al., 2008) and 100 µg hCRH i.v. produced maximal serum cortisol concentrations of 210 ng/ml (Dinan et al., 1999; Scott et al., 1999b). This indicates a higher maximum release of ACTH and cortisol following corticotrophinergic stimulation than after vasopressinergic co-activation. This is also illustrated in trials where dDAVP induced a dose-dependent ACTH release for 5 and 10 µg, but not for 15 µg dDAVP (Scott et al., 1999a) and CRH augmented the vasopressin-induced V_3 effects when administered concomitantly with dDAVP (Favrod-Coune et al., 1993). Such limited vasopressinergic co-activation may be determined by low levels of endogenous CRH, since this study was performed late in the morning and early afternoon, when circadian activity of the HPA axis is relatively low.

The HPA axis can also be activated by homeostatic perturbations, like hypotension causing an indirect stress response via the sympatho-medullary route. dDAVP-induced blood pressure reduction seems to be dependent on V_2 stimulation, causing prostaglandin release from vascular endothelium (Aldasoro et al., 1997; Medina et al., 1999). A reduction in peripheral resistance can activate sympathetic outflow via fibres descending from the vasoconstrictor regions of the medulla oblongata. Concomitantly, direct stimulation of sympathetic outflow fibres terminating on the adrenal cortex can release adrenaline, which in turn might induce ACTH release via AVP neurons (Aldasoro et al., 1997; Scott and Dinan, 2002). On average, 10 µg dDAVP reduced DBP by 7.2 mmHg, and the incremental 30 µg infusion by 8.5 mmHg in the current study. HR showed average compensatory increases of 6.0 bpm after the bolus and 9.7 bpm with the infusion. It could be argued that even these small cardiovascular changes signify an activation of the ANS, inducing ACTH release via alternative routes. However, indirect stress measures (saliva alpha amylase and serum prolactin) that indicate catecholamine-mediated ANS activity via the sympathoadrenal medullary route (Aldasoro et al., 1997;

Rohleder et al., 2004) remained unaffected by either dDAVP administration mode. Thus, dDAVP's effects on the HPA axis do not seem to be mediated by peripheral stress effects, at least if subjects are kept supine during the test to minimize the blood-pressure-lowering effects of dDAVP.

dDAVP displayed a differential concentration-effect relationship for the neuroendocrine parameters on the one hand and cardiovascular and coagulatory parameters on the other. dDAVP's V_2 -mediated effects (HR and vWF) were concentration dependent, which was not the case for its V_3 -mediated effects (ACTH and cortisol release). The maximal plasma concentrations ($C_{\max}$) attained with 30 µg dDAVP were nearly twice (1.8-fold) as large as those reached with 10 µg dDAVP. This difference was reflected by the concentration dependence of the cardiovascular and coagulatory effects, but not of the neuroendocrine responses, which were similar for the two doses.

The results suggest that 10 µg dDAVP is a safe pharmacological function test in healthy volunteers and patients, at least if some potential restrictions are considered. Neither 10 µg dDAVP nor 30 µg dDAVP affected serum osmolality with fluid restriction, but dDAVP can cause a reduced osmolality if liberal water consumption is allowed. dDAVP clearly induced vWF release, but this is unlikely to produce coagulatory complications. The intravenous administration of dDAVP stimulates the release of vWF and factor VIII from the vascular endothelium via V_2 receptors (Lethagen, 1994). At the same time, dDAVP releases tissue plasminogen activator (tPA), which mitigates the prothrombotic effects of vWF (Burggraaf et al., 1994). vWF itself is degraded by the vWF cleaving protease ADAMTS13. Also, a twice higher dose of dDAVP compared with the present trial (0.3 versus 0.13 µg/kg) lead to (maximal) vWF release (Lethagen, 1994) without the occurrence of coagulation-related AEs in healthy volunteers. The prothrombotic effects of 10 µg dDAVP thus appear to be self-limiting, at least in healthy volunteers. Susceptible patients, however, may be at an increased risk of thrombo-embolic events following dDAVP-induced vWF-elevations, although this is only suggested by rare case reports of patients who developed an acute myocardial infarction after administration of dDAVP for their haemophilia or von Willebrand's disease (Follenius et al., 1982). Therefore, it is probably sensible to avoid higher doses of dDAVP, and to exclude patients with multiple cardiovascular risk factors or a (past) history of ischemic heart disease or a (congenital) ADAMTS13 deficiency. In this study, dDAVP had its maximum neuroendocrine effects at a dose of 10 µg, with limited coagulatory and cardiovascular manifestations. At this dose, the risk of thrombotic complications seems very small in patients who suffer from depression but have no clearly elevated cardiovascular risk.

In conclusion, administering 10 µg dDAVP intravenously over 1 min is an effective pharmacological tool to induce vasopressinergic HPA axis activation in healthy volunteers. Under low corticotrophinergic conditions, this challenge produces a clear but limited co-activation of pituitary ACTH-release via the V_3 . A 10 µg dDAVP bolus does not cause much systemic effects, and avoids non-specific stress responses. The effects on serum osmolality and coagulation are limited, although the safety in specific risk populations remains to be established.

Higher doses of dDAVP are not expected to produce much more informative vasopressinergic co-activation, and could induce adverse and confounding V₂-mediated effects.

Acknowledgements

This work was supported by the Schering-Plough Research Institute.

References

- Agerso H, Seiding LL, Riis A, Lovgren U, Karlsson MO, Senderovitz T (2004) Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. *Br J Clin Pharmacol* 58: 352–358.
- Aguilera G, Rabadan-Diehl C (2000) Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. *Regul Pept* 96: 23–29.
- Aldasoro M, Medina P, Vila JM, Otero E, Martinez-Leon JB, Lluch S (1997) Endothelium-dependent relaxation of human saphenous veins in response to vasopressin and desmopressin. *J Vasc Surg* 25: 696–703.
- Burggraaf J, Schoemaker HC, Kroon JM, Huisman L, Kluft C, Cohen AF (1994) Influence of 1-desamino-8-D-vasopressin on endogenous fibrinolysis, haemodynamics and liver blood flow in healthy subjects. *Clin Sci (Lond)* 86: 497–503.
- Callreus T, Odeberg J, Lundin S, Hoglund P (1999) Indirect-response modeling of desmopressin at different levels of hydration. *J Pharmacokinet Biopharm* 27: 513–529.
- Craighead M, Milne R, Campbell-Wan L, et al. (2008) Characterization of a novel and selective V_{1B} receptor antagonist. *Prog Brain Res* 170: 527–535.
- Dinan TG, Lavelle E, Scott LV, Newell-Price J, Medbak S, Grossman AB (1999) Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity. *J Clin Endocrinol Metab* 84: 2238–2240.
- Dinan TG, O'Brien S, Lavelle E, Scott LV (2004) Further neuroendocrine evidence of enhanced vasopressin V₃ receptor responses in melancholic depression. *Psychol Med* 34: 169–172.
- Dinan TG, Scott LV (2005) Anatomy of melancholia: focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressin. *J Anat* 207: 259–264.
- Evans DL, Charney DS, Lewis L, et al. (2005) Mood disorders in the medically ill: scientific review and recommendations. *Biol Psychiatry* 58: 175–189.
- Favrod-Coune C, Raux-Demay MC, Proeschel MF, Bertagna X, Girard F, Luton JP (1993) Potentiation of the classic ovine corticotrophin releasing hormone stimulation test by the combined administration of small doses of lysine vasopressin. *Clin Endocrinol (Oxf)* 38: 405–410.
- Fjellestad-Paulsen A, d'Agay-Abensour L, Hoglund P, Rambaud JC (1996) Bioavailability of 1-deamino-8-D-arginine vasopressin with an enzyme inhibitor (aprotinin) from the small intestine in healthy volunteers. *Eur J Clin Pharmacol* 50: 491–495.
- Follenius M, Brandenberger G, Hietter B, Simeoni M, Reinhardt B (1982) Diurnal cortisol peaks and their relationships to meals. *J Clin Endocrinol Metab* 55: 757–761.
- Gijssman HJ, van Gerven JM, Tieleman MC, et al. (1998) Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. *J Clin Psychopharmacol* 18: 289–295.
- Holsboer F (1983) The dexamethasone suppression test in depressed patients: clinical and biochemical aspects. *J Steroid Biochem* 19: 251–257.
- Holsboer F (2000) The corticosteroid receptor hypothesis of depression. *Neuropsychopharmacology* 23: 477–501.
- Lethagen S (1994) Desmopressin (DDAVP) and hemostasis. *Ann Hematol* 69: 173–180.
- Medina P, Segarra G, Vila JM, Chuan P, Domenech C, Lluch S (1999) V₂-receptor-mediated relaxation of human renal arteries in response to desmopressin. *Am J Hypertens* 12: 188–193.
- Musselman DL, Betan E, Larsen H, Phillips LS (2003) Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. *Biol Psychiatry* 54: 317–329.
- Odeberg JM, Callreus T, Lundin S, Roth EB, Hoglund P (2004) A pharmacokinetic and pharmacodynamic study of desmopressin: evaluating sex differences and the effect of pre-treatment with piroxicam, and further validation of an indirect response model. *J Pharm Pharmacol* 56: 1389–1398.
- Pariante CM, Lightman SL (2008) The HPA axis in major depression: classical theories and new developments. *Trends Neurosci* 31: 464–468.
- Ramasubbu R (2002) Insulin resistance: a metabolic link between depressive disorder and atherosclerotic vascular diseases. *Med Hypotheses* 59: 537–551.
- Rembratt A, Graugaard-Jensen C, Senderovitz T, Norgaard JP, Djurhuus JC (2004) Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at day-time versus night-time in healthy men aged 55–70 years. *Eur J Clin Pharmacol* 60: 397–402.
- Ring RH (2005) The central vasopressinergic system: examining the opportunities for psychiatric drug development. *Curr Pharm Des* 11: 205–225.
- Rohleder N, Nater UM, Wolf JM, Ehler U, Kirschbaum C (2004) Psychosocial stress-induced activation of salivary alpha-amylase: an indicator of sympathetic activity? *Ann N Y Acad Sci* 1032: 258–263.
- Scott LV, Dinan TG (1998) Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression. *Life Sci* 62: 1985–1998.
- Scott LV, Dinan TG (2002) Vasopressin as a target for antidepressant development: an assessment of the available evidence. *J Affect Disord* 72: 113–124.
- Scott LV, Medbak S, Dinan TG (1999a) ACTH and cortisol release following intravenous desmopressin: a dose-response study. *Clin Endocrinol (Oxf)* 51: 653–658.
- Scott LV, Medbak S, Dinan TG (1999b) Desmopressin augments pituitary-adrenal responsivity to corticotropin-releasing hormone in subjects with chronic fatigue syndrome and in healthy volunteers. *Biol Psychiatry* 45: 1447–1454.
- Smarius LJ, Jacobs GE, Hoeberechts-Lebrandt DH, et al. (2008) Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. *J Psychopharmacol* 22: 426–433.
- Spiga F, Harrison L, Macsweeney C, Thomson F, Craighead M, Lightman S (2009) Effect of vasopressin 1b receptor blockade on the hypothalamic-pituitary-adrenal response of chronically stressed rats to a heterotypic stressor. *J Endocrinol* 200(3): 285–291.